Schafer Cullen Capital Management Inc. trimmed its position in GlaxoSmithKline plc (NYSE:GSK) by 40.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,123,538 shares of the pharmaceutical company’s stock after selling 775,894 shares during the quarter. Schafer Cullen Capital Management Inc.’s holdings in GlaxoSmithKline were worth $39,852,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in the stock. Shufro Rose & Co. LLC increased its holdings in GlaxoSmithKline by 20.7% in the 3rd quarter. Shufro Rose & Co. LLC now owns 8,750 shares of the pharmaceutical company’s stock worth $355,000 after acquiring an additional 1,500 shares in the last quarter. Profund Advisors LLC increased its holdings in GlaxoSmithKline by 3.0% in the 4th quarter. Profund Advisors LLC now owns 52,264 shares of the pharmaceutical company’s stock worth $1,854,000 after acquiring an additional 1,519 shares in the last quarter. Pinkerton Retirement Specialists LLC increased its holdings in GlaxoSmithKline by 2.7% in the 3rd quarter. Pinkerton Retirement Specialists LLC now owns 59,426 shares of the pharmaceutical company’s stock worth $2,433,000 after acquiring an additional 1,578 shares in the last quarter. Eagle Asset Management Inc. increased its holdings in GlaxoSmithKline by 15.3% in the 3rd quarter. Eagle Asset Management Inc. now owns 12,870 shares of the pharmaceutical company’s stock worth $526,000 after acquiring an additional 1,708 shares in the last quarter. Finally, Balentine LLC increased its holdings in GlaxoSmithKline by 34.2% in the 3rd quarter. Balentine LLC now owns 7,301 shares of the pharmaceutical company’s stock worth $296,000 after acquiring an additional 1,862 shares in the last quarter. 10.96% of the stock is owned by institutional investors.
Shares of GlaxoSmithKline plc (NYSE GSK) traded down $0.39 on Tuesday, reaching $36.89. 2,140,632 shares of the company’s stock were exchanged, compared to its average volume of 4,136,411. The company has a debt-to-equity ratio of 4.09, a quick ratio of 0.39 and a current ratio of 0.60. GlaxoSmithKline plc has a twelve month low of $34.52 and a twelve month high of $44.53. The stock has a market cap of $92,433.30, a price-to-earnings ratio of 46.70, a P/E/G ratio of 2.26 and a beta of 0.95.
GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.03. GlaxoSmithKline had a net margin of 4.97% and a return on equity of 130.63%. The business had revenue of $10.14 billion during the quarter, compared to analyst estimates of $9.89 billion. equities research analysts expect that GlaxoSmithKline plc will post 2.95 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 12th. Investors of record on Friday, February 23rd will be issued a $0.633 dividend. The ex-dividend date is Thursday, February 22nd. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.50. This represents a $2.53 dividend on an annualized basis and a dividend yield of 6.86%. GlaxoSmithKline’s dividend payout ratio (DPR) is 320.26%.
Several equities research analysts recently issued reports on GSK shares. UBS reissued a “buy” rating on shares of GlaxoSmithKline in a report on Monday, January 15th. Zacks Investment Research raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $42.00 target price for the company in a report on Tuesday, January 9th. Argus cut their price objective on shares of GlaxoSmithKline to $40.00 and set a “buy” rating for the company in a report on Thursday, November 30th. TheStreet lowered shares of GlaxoSmithKline from a “b-” rating to a “c” rating in a report on Wednesday, February 7th. Finally, ValuEngine lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $38.77.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://ledgergazette.com/2018/03/20/schafer-cullen-capital-management-inc-has-39-85-million-position-in-glaxosmithkline-plc-gsk.html.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.